Registration is free. Please confirm your participation before September 19, 2016Confirm my presence
After years in big pharma, Dr. Martin Mackay moved to the biotech arena. He is currently the Executive Vice President, Head of Research &
Development at Alexion Pharmaceuticals, Inc. He leads the Research & Development organization in a range of disease areas (hematology,
nephrology, neurology, metabolic, transplant, and inflammatory disorders).
Prior to joining Alexion, Martin was the President of Research & Development at AstraZeneca Pharmaceuticals. Before that, Martin was the
President of PharmaTherapeutics Research & Development at Pfizer. His career at Pfizer spanned 15 years, where he held various leadership roles,
including the President of Research & Development. He also held roles at Ciba Pharmaceuticals and Beecham Pharmaceuticals.
He serves on the Scientific and Regulatory Committee of the industry trade group PhRMA and co-chairs the US-India BioPharma & Healthcare
Summit Advisory Board. Martin is a Visiting Professor at the University of Lincoln, UK.
An example of a success in applied and translational research in Montreal is the acquisition of Enobia Pharma by Alexion for $1.1 billion in 2011.
Enobia’s lead product, an enzyme-replacement therapy for patients suffering from hypophosphatasia, was originally developed at the Université de
Montréal’s Biochemistry laboratories through the work of Professor Philippe Crine.
A continental breakfast will be served at 8:15 a.m.
Registration is free. Please confirm your participation before September 19, 2016